ArticleMedicine2026
Immunomodulatory roles of the HLA family and B2M in atherosclerosis: Diagnostic biomarkers and thrombosis risk.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Atherosclerosis (AS), a chronic inflammatory disease driven by lipid accumulation and immune dysregulation, predisposes to acute cardiovascular events via plaque rupture and thrombosis. The molecular mechanisms linking immune microenvironment imbalance to plaque instability remain incompletely defined. Utilizing the GSE100927 dataset (69 AS patients vs 35 controls), we identified differentially expressed genes (DEGs) and constructed co-expression networks via weighted gene co-expression network analysis. Hub genes were intersected with DEGs to determine core genes. Immune cell infiltration was quantified using Cell-type Identification By Estimating Relative Subsets Of RNA Transcripts, and correlations between core genes and immune subsets were assessed. Diagnostic potential was evaluated by receiver operating characteristic (ROC) analysis. We identified 2596 DEGs (1575 up-/1021 downregulated) in AS tissues. Weighted gene co-expression network analysis revealed 3 disease-associated modules, yielding 54 hub genes. Intersection with DEGs identified 12 core genes, including HLA-G, HLA-A, HLA-C, and beta-2-microglobulin (B2M). These genes were enriched in "major histocompatibility complex class Ib-mediated antigen presentation" and significantly upregulated in AS (P < .001). Immune profiling showed elevated M0 macrophages and reduced resting CD4+ memory T cells in AS (P < .0001). Expression of HLA-G, HLA-A, HLA-C, and B2M positively correlated with M0 macrophages and negatively with CD4+ T cells (P < .001). ROC analysis within the GSE100927 dataset demonstrated high diagnostic accuracy for distinguishing AS samples from controls (HLA-G/A/C area under the ROC curve = 0.94; B2M area under the ROC curve = 0.87). HLA-G, HLA-A, HLA-C, and B2M modulate macrophage and T cell functions, driving immune dysregulation in AS. This immune imbalance is associated with plaque instability and may contribute to thrombosis risk, highlighting the potential of these molecules as diagnostic biomarkers and therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.